PATHOPHYSIOLOGICAL SIGNIFICANCE OF INSULIN RESISTANCE IN PCOS AND PREVENTIVE APPROACHES TO MANAGEMENT
;
Polycystic ovary syndrome, insulin resistance, hyperinsulinemia, ovulatory dysfunction, anovulation, hyperandrogenism, metabolic syndrome, dyslipidemia, obesity, type 2 diabetes mellitus, cardiovascular diseases, prevention, lifestyle, pharmacotherapyAbstrak
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder that is widely prevalent among women of reproductive age. This article analyzes the mechanisms underlying the development of the syndrome, with particular emphasis on the role of insulin resistance, as well as its clinical manifestations, diagnostic methods, and approaches to prevention and treatment.Evidence suggests that insulin resistance is one of the key factors in the pathogenesis of PCOS. Through hyperinsulinemia, it enhances androgen synthesis in the ovaries, which leads to disruption of ovulation, infertility, and the development of various metabolic complications. A comprehensive approach, including the adoption of a healthy lifestyle, rational use of pharmacological agents, and early diagnosis, plays a crucial role in reducing PCOS-related disorders.Furthermore, individualized strategies aimed at controlling insulin resistance are effective in improving both reproductive and overall health outcomes.
Iqtiboslar
Azziz R., et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057.
Bozdag G., et al. The prevalence and phenotypic features of PCOS: a systematic review. Human Reproduction. 2016;31(12):2841–2855.
Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews. 2012;33(6):981–1030.
Goodarzi M.O., et al. Pathogenesis of PCOS: the role of insulin. Fertility and Sterility. 2011;95(3):831–842.
Stepto N.K., et al. Intrinsic insulin resistance in PCOS. Human Reproduction. 2013;28(3):777–784.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774–800
Moran L.J., et al. Impaired glucose tolerance and type 2 diabetes in PCOS. Human Reproduction Update. 2010;16(4):347–363.
González F. Inflammation in PCOS. Steroids. 2012;77(4):300–305.
Teede H.J., et al. International guideline for PCOS management. Human Reproduction. 2018;33(9):1602–1618.
Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine. 1996;335(9):617–623.
Goodarzi M.O., Dumesic D.A., Chazenbalk G., Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology. 2011;7(4):219–231.
Franks S. Polycystic ovary syndrome. New England Journal of Medicine. 1995;333(13):853–861.
Escobar-Morreale H.F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018;14(5):270–284.
Legro R.S. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565–4592.
Balen A.H., et al. Polycystic ovary syndrome: pathophysiology and treatment. The Lancet. 2003;361(9368):1417–1423.
Clayton R.N. Clinical presentation of polycystic ovary syndrome. International Journal of Obesity. 2000;24(S2):S20–S24.
Wild R.A., et al. Cardiovascular risk in women with polycystic ovary syndrome. Fertility and Sterility. 2010;94(1):7–12.
Ehrmann D.A. Polycystic ovary syndrome. New England Journal of Medicine. 2005;352:1223–1236.
Norman R.J., et al. Metabolic approaches to the treatment of PCOS. Human Reproduction Update. 2007;13(6):571–587.
Meyer C., et al. Endothelial dysfunction in PCOS. Human Reproduction Update. 2005;11(5):487–496.
Barry J.A., et al. The psychological impact of PCOS. Human Reproduction. 2011;26(1):15–24.
Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for PCOS assessment and management. Human Reproduction. 2018;33(9):1602–1618.
Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in PCOS. Cochrane Database Syst Rev. 2011;(2):CD007506.
Marsh KA, Steinbeck KS, Atkinson FS, Petocz P, Brand-Miller JC. Low glycemic index diet in PCOS. Am J Clin Nutr. 2010;92(1):83–92.
Pasquali R, Gambineri A. Obesity and PCOS. J Endocrinol Invest. 2011;34(8):644–649.
Lord JM, Flight IH, Norman RJ. Metformin therapy in PCOS. Cochrane Database Syst Rev. 2003;(3):CD003053.
Dunaif A. Insulin resistance in PCOS. Endocr Rev. 1997;18(6):774–800.
Ehrmann DA. Metabolic features of PCOS. N Engl J Med. 2005;352:1223–1236.
Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clinical Endocrinology. 2021;94(4):531–541.
Diamanti-Kandarakis E, et al. Insulin resistance and hyperandrogenism in PCOS. Endocrine Reviews. 2012;33(6):981–1030.
Gambineri A, et al. Metabolic syndrome in PCOS. European Journal of Endocrinology. 2002;146(6):721–728.
Azziz R, et al. Polycystic ovary syndrome: pathogenesis and clinical implications. Nature Reviews Endocrinology. 2016;12(5):278–288.
##submission.downloads##
Nashr qilingan
Nashr
Bo'lim
Iqtibos keltirish tartibi
